CST
GILD icon

Charles Schwab Trust’s Gilead Sciences GILD Stock Holding History

Charles Schwab Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,810
Closed -$252K – 173
2026
Q1 		$252K Buy
+1,810
New +$253K 0.02% 150
2023
Q3 		– Sell
-3,337
Closed -$257K – 166
2023
Q2 		$257K Buy
+3,337
New +$266K 0.03% 127

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab Trust's GILD Position: Q2 2026 in Review

Charles Schwab Trust sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,810 shares — an estimated $252K sold.

Charles Schwab Trust first reported a position in GILD in Q2 2023 and held it in 2 quarters. The position peaked at $257K in Q2 2023. 2,265 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Charles Schwab Trust reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab Trust sold 1,810 Gilead Sciences shares in Q2 2026, an estimated $252K.
  • Charles Schwab Trust first reported a position in Gilead Sciences in Q2 2023 and held it in 2 quarters.
  • Charles Schwab Trust's Gilead Sciences position peaked at $257K in Q2 2023.
  • 2,265 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Charles Schwab Trust's 13F filing for Q2 2026, filed 10 Jul 2026.